- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06308627
A One-year Trajectory of Depression Status Changes in Elderly Patients With MCI and SD: a Longitudinal Cohort Study
March 12, 2024 updated by: Dan Ting Chen, Fujian Medical University
A One-year Trajectory of Depression Status Changes in Elderly Patients With Mild Cognitive Impairment and Subthreshold Depression: a Longitudinal Cohort Study
The purpose of this study is to investigate the one-year trajectory of changes in depression status in elderly patients with mild cognitive impairment and subthreshold depression, and to explore relevant risk factors for predicting changes in depression status.
This one-year prospective longitudinal follow-up study involved 400 (expected) subjects who met the diagnostic criteria for mild cognitive impairment combined with subthreshold depression in the elderly, and their depressive status was assessed using the Geriatric Depression Scale (GDS).
Follow up monitoring of depression status at 6 and 12 months.
Obtain factors related to changes in depressive status (such as age, gender, education level, cognitive function, anxiety level, sleep status, social support, psychological resilience, social network, etc.).
By studying the longitudinal trajectory of depression status in elderly patients with mild cognitive impairment and subthreshold depression, a multi state Markov model with time and state discreteness is constructed, namely: State 1 (normal); State 2 (subliminal depression); State 3 (mild depression); State 4 (moderate depression); State 5 (severe depression).
Deeply explore and analyze the impact of certain factors and indicators on the transition between states, and estimate the probability of transition between states.
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Estimated)
400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hong Li
- Phone Number: 18120826271
- Email: leehong99@126.com
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China, 350000
- Recruiting
- Fujian Provincial Hospital
-
Contact:
- Hong Li
- Phone Number: 18120826271
- Email: leehong99@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Select elderly patients with mild cognitive impairment and subthreshold depression who meet the inclusion and exclusion criteria from multiple elderly care institutions, a tertiary hospital in Fuzhou, and communities in Fujian Province as the research subjects.
Description
Inclusion Criteria:
- Age: ≥ 60 years old
- Meets the diagnostic criteria for mild cognitive impairment and subthreshold depression
- Having basic comprehension and verbal expression skills
- Voluntarily participate in this study and sign an informed consent form.
Exclusion Criteria:
- Diagnosed as depression patients, including patients with organic mental disorders and patients with a history of depression related mental disorders
- Cognitive impairment caused by other diseases (such as neurological and psychiatric disorders, metabolic disorders, poisoning, infections, etc.)
- Severe heart, liver, and kidney diseases
- Serious chronic diseases and complications, such as congestive heart failure, hypertension, diabetes and other diseases with serious complications
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depressive state
Time Frame: 2023.6.1-2024.7.1
|
The Geriatric Depression Scale (GDS-15) is used to investigate the psychological feelings of patients in the past week.
Result evaluation criteria: The total score range is 0-15 points, with higher scores indicating more severe depression.
1-5 points are subthreshold depression, 6-7 points are mild depression, 8-11 points are moderate depression, and 12-15 points are severe depression.
|
2023.6.1-2024.7.1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General information of patients
Time Frame: 2023.6.1-2024.7.1
|
Using a self-made general information scale, such as age, gender, education level, and other basic personal information
|
2023.6.1-2024.7.1
|
Cognitive
Time Frame: 2023.6.1-2024.7.1
|
The Mini Mental State Examination (MMSE) consists of 30 items, with a total score range of 0-30 points.
A total score below 27 indicates cognitive impairment.
The diagnostic criteria for dementia are illiteracy ≤ 17 points, primary school level ≤ 20 points, secondary school level (including vocational school) ≤ 22 points, and university level (including vocational school) ≤ 23 points.
|
2023.6.1-2024.7.1
|
Cognitive
Time Frame: 2023.6.1-2024.7.1
|
Montreal Cognitive Assessment (MoCA) is an assessment tool used for rapid screening of mild cognitive impairment.
The total score is 30 points, and the higher the score, the better the cognitive function of the research subject.
Literacy group ≤ 13 points, primary school group ≤ 19 points, and middle school and above group ≤ 24 points can be judged as cognitive impairment.
|
2023.6.1-2024.7.1
|
Activity of Daily Living
Time Frame: 2023.6.1-2024.7.1
|
The Activities of Daily Living (ADL) scale adopts a Liket four level rating.
The evaluation results can be analyzed based on total score, dimension score, and individual score.
A total score of 20 is considered completely normal, while a score above 20 indicates varying degrees of functional decline.
A score of 1 for each item indicates normal functionality, while a score of 2-4 indicates decreased functionality.
|
2023.6.1-2024.7.1
|
Anxiety
Time Frame: 2023.6.1-2024.7.1
|
The Self Rating Anxiety Scale (SAS) has a total of 20 items, of which 5, 9, 13, 17, and 19 items are scored in reverse.
The scale adopts a 1-4 level scoring method (1 point for no or very little time; 2 points for a small portion of time; 3 points for a considerable amount of time; 4 points for the vast majority or all of time).
Individuals fill in the scale based on their own situation in the most recent week, multiply the calculated total score by 1.25, take an integer as the standard score, and use it as a statistical indicator.
The higher the standard score, the more severe the anxiety level of the individual.
|
2023.6.1-2024.7.1
|
Social Function
Time Frame: 2023.6.1-2024.7.1
|
The Social Support Rating Scale (SSRS) includes three dimensions: objective support, subjective support, and support utilization, with a total of 10 items: 1 point (none) to 4 points (full support).
The higher the score in each dimension, the more support received.
|
2023.6.1-2024.7.1
|
Social Function
Time Frame: 2023.6.1-2024.7.1
|
The Lubben Social Network Scale (LSNS-6) is used to measure the structural characteristics of individual family and friend networks, as well as the supporting functions played by the network, in order to reflect the social network level of the respondents.
It consists of two parts: the home network and the friend network, each with three items, totaling six items.
Each entry has 5 options, with a score of 0-5 points and a total score of 0-30 points.
The higher the score, the higher the level of social network, and<12 points indicates insufficient social network.
|
2023.6.1-2024.7.1
|
Sleep Quality
Time Frame: 2023.6.1-2024.7.1
|
The Pittsburgh Sleep Quality Index (PSQI) has a total of 19 items, divided into 7 components: subjective sleep quality, time to fall asleep, sleep time, sleep efficiency, sleep disorders, hypnotic drugs, and daytime function.
The higher the total score, the worse the sleep quality.
|
2023.6.1-2024.7.1
|
Resilience
Time Frame: 2023.6.1-2024.7.1
|
The Corner Davidson Resilience Scale (CDRISC) consists of 10 items and uses the Likert 5-point scoring system.
A score of 0-4 indicates "never", "rarely", "sometimes", "often", and "always", with higher scores indicating higher levels of psychological resilience.
|
2023.6.1-2024.7.1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: DanTing Chen, Fujian Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2023
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
March 4, 2024
First Submitted That Met QC Criteria
March 12, 2024
First Posted (Actual)
March 13, 2024
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K2022-03-074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel